# Aprea Therapeutics (APRE) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/APRE
## Company Profile
- Ticker: APRE
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology
## Stock Data
- Close: 0.6 USD
- Market cap: 9462917.4192 USD
- Last updated: 2026-10-13
## Business Overview
### DNA Damage Response Oncology
Aprea Therapeutics develops precision medicines that exploit vulnerabilities in cancer-cell DNA replication and repair. Its programs target biomarker-defined tumors while seeking to limit effects on healthy cells.
### APR-1051
APR-1051 is a selective oral WEE1 inhibitor in the Phase 1 ACESOT-1051 study for advanced solid tumors. The program is designed to improve the therapeutic window relative to earlier WEE1 inhibitors.
### Biomarker-Directed Expansion
Aprea is expanding APR-1051 in uterine serous carcinoma and cyclin E-overexpressing platinum-resistant ovarian cancer. It also plans combination work in HPV-positive head-and-neck cancer and colorectal cancer.
### ATRN-119
ATRN-119 is a macrocyclic ATR inhibitor that has completed Phase 1 dose escalation. Aprea is evaluating potential combination development with immunotherapy, chemotherapy, antibody-drug conjugates, and radiation.
## Why The Stock Is Moving

As of Oct 13, 2026, APRE closed up 1.16% at $0.6000. No new same-company headline was identified in the current news window.

## Future Catalysts

- Clinical data update from the Phase 1 ACESOT-1051 study of APR-1051 at a medical meeting in the fourth quarter of 2026.
- Potential entry of Aprea's macrocyclic DYRK1A/B inhibitor into IND-enabling studies in the fourth quarter of 2026.
- Completion of APR-1051 dose escalation and backfill expansion in the second quarter of 2027.

## Drug Assets

- APR-1051

## Recent News
- 2026-10-05 12:30 EST — [Aprea Therapeutics to Present at October Conferences](https://biopharmsignal.com/news/APRE/aprea-therapeutics-to-present-at-october-conferences-f6da2a3c) — Source: Aprea Therapeutics
- 2026-09-22 12:30 EST — [Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium](https://biopharmsignal.com/news/APRE/aprea-therapeutics-to-present-updated-interim-phase-1-data-on-wee1-inhibitor-apr-d9feffe5) — Source: Aprea Therapeutics
- 2026-09-10 12:00 EST — [Aprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference](https://biopharmsignal.com/news/APRE/aprea-therapeutics-to-present-at-h-c-wainwright-28th-annual-global-investment-co-a2296a0e) — Source: Aprea Therapeutics
- 2026-08-28 12:15 EST — [Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs](https://biopharmsignal.com/news/APRE/aprea-therapeutics-announces-expansion-of-intellectual-property-portfolio-for-pr-9fac98dc) — Source: Aprea Therapeutics
- 2026-08-12 12:30 EST — [Aprea Therapeutics Announces Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/APRE/aprea-therapeutics-announces-second-quarter-2026-financial-results-96f89b58) — Source: Aprea Therapeutics